<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639324</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15-12310</org_study_id>
    <secondary_id>NCI-2018-01661</secondary_id>
    <nct_id>NCT03639324</nct_id>
  </id_info>
  <brief_title>Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL</brief_title>
  <acronym>RIVe-CLL/SLL</acronym>
  <official_title>Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL/SLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination&#xD;
      with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small&#xD;
      lymphocytic lymphoma (CLL/SLL) following a lead-in period with idelalisib and rituximab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 1, multicenter, dose-escalation study is designed to find the Recommended Phase 2&#xD;
      Dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with&#xD;
      relapsed or refractory CLL/SLL and to assess the clinical activity of the combination with&#xD;
      rituximab in patients with relapsed or refractory CLL/SLL and to assess the clinical activity&#xD;
      of the combination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Slow Accrual&#xD;
  </why_stopped>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Actual">October 18, 2021</completion_date>
  <primary_completion_date type="Actual">October 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Patients will start on dose level 1 of venetoclax in combination with rituximab and idelalisib, then escalate or de-escalate (if lower dose is available) based upon the estimated probabilities of toxicity from an extension of the continual reassessment method for 2 agents.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Find the RP2D of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)</measure>
    <time_frame>41 Months</time_frame>
    <description>Determine the recommended phase 2 dose of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory CLL/SLL following a lead-in period with idelalisib and rituximab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation: Determine adverse events (AEs) reported using criteria in the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0</measure>
    <time_frame>63 Months</time_frame>
    <description>Observed adverse events of treatment with idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory CLL/ SLL following a lead-in period with idelalisib and rituximab utlizing CTCAE Version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of cumulative complete response (CR) rate.</measure>
    <time_frame>52 Months</time_frame>
    <description>Determine the cumulative CR rate to the study regimen at 7 and 13 months using the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summarize the objective response rate.</measure>
    <time_frame>52 Months</time_frame>
    <description>Determine the cumulative overall disease response to the study regimen at 7 and 13 months using the 2008 IWCLL criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) rate</measure>
    <time_frame>52 Months</time_frame>
    <description>Estimate the rate of undetectable minimal residual disease (MRD) status for idelalisib and venetoclax in combination with rituximab using 4-color flow cytometry in peripheral blood and/or bone marrow for responding patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>63 Months</time_frame>
    <description>determine the OS rate (at 24 months following initiation of venetoclax) for idelalisib and venetoclax in combination with rituximab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate</measure>
    <time_frame>63 Months</time_frame>
    <description>Determine the progression-free survival (PFS) rate (at 24 months following initiation of venetoclax) for idelalisib and venetoclax in combination with rituximab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the combination of idelalisib and venetoclax.</measure>
    <time_frame>7 Years</time_frame>
    <description>Determine the idelalisib and venetoclax plasma concentrations measured at designated time points throughout the study: pre-Tx; C1D1; C1D15; C1D22; C1D29; C3D1; C7D22; C13D222; at DLT (if feasible); at relapse (if feasible)]</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>CLL</condition>
  <condition>Relapsed CLL</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Relapsed Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>SLL</condition>
  <condition>Relapsed Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Combination 1-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>idelalisib + venetoclax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Combination 1-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>idelalisib + venetoclax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Combination 1-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>idelalisib + venetoclax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Combination 1-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>idelalisib + venetoclax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Trial Dose Combination 2-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>idelalisib + venetoclax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Trial Dose Combination 2-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>idelalisib + venetoclax</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose combination 1-1</intervention_name>
    <description>100 mg QD of idelalisib + 100 mg QD of venetoclax</description>
    <arm_group_label>Dose Combination 1-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dose combination 1-2</intervention_name>
    <description>100 mg QD of idelalisib + 200 mg QD of venetoclax</description>
    <arm_group_label>Dose Combination 1-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose combination 1-3</intervention_name>
    <description>100 mg BID of idelalisib + 200 mg QD of venetoclax</description>
    <arm_group_label>Dose Combination 1-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dose combination 1-4</intervention_name>
    <description>150 mg BID of idelalisib + 200 mg QD of venetoclax</description>
    <arm_group_label>Dose Combination 1-4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sub-Trial: Dose combination 2-1</intervention_name>
    <description>100 mg BID of idelalisib + 100 mg QD of venetoclax</description>
    <arm_group_label>Sub-Trial Dose Combination 2-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sub-Trial: Dose combination 2-2</intervention_name>
    <description>150 mg BID of idelalisib + 100 mg QD of venetoclax</description>
    <arm_group_label>Sub-Trial Dose Combination 2-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age ≥ 18 years of age. Relapsed or refractory B-cell CLL or biopsy-proven SLL. Treatment&#xD;
        required in the opinion of the investigator&#xD;
&#xD;
        Must have had at least one standard treatment with a regimen containing at least one of the&#xD;
        following agents/classes of agents; and where specified, must also meet the treatment&#xD;
        duration, progression, and/or relapse criteria for that class of agent:&#xD;
&#xD;
          -  Fludarabine&#xD;
&#xD;
          -  An alkylator (eg, chlorambucil, bendamustine)&#xD;
&#xD;
          -  A BTK inhibitor (eg, ibrutinib, acalabrutinib); and must have progressed or relapsed &gt;&#xD;
             6 months after last BTK inhibitor treatment&#xD;
&#xD;
          -  An anti-CD20 monoclonal antibody (eg, rituximab, obinutuzumab)&#xD;
&#xD;
          -  A BCL-2-family protein inhibitor (eg, venetoclax, navitoclax); and&#xD;
&#xD;
               -  if best response is &lt; CR with BCL-2-family protein inhibitor treatment&#xD;
&#xD;
               -  must have had ≥ 1 year of BCL-2-family protein inhibitor treatment; and&#xD;
&#xD;
               -  must have progressed &gt; 6 months after last BCL-2-family protein inhibitor&#xD;
                  treatment&#xD;
&#xD;
               -  if best response is CR with BCL-2-family protein inhibitor treatment&#xD;
&#xD;
               -  must have relapsed ≥ 1 year after last BCL-2-family protein inhibitor treatment&#xD;
&#xD;
          -  A PI3K inhibitor (eg, idelalisib, duvelisib, TGR-1202, copanlisib, buparlisib); and&#xD;
             must have progressed or relapsed &gt; 6 months after last treatment with the PI3K&#xD;
             inhibitor (NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 2ND-STEP REGISTRATION)&#xD;
&#xD;
        Prior allogeneic stem cell transplant allowed provided the following criteria are met:&#xD;
&#xD;
          -  ≥ 12 months have elapsed since allogeneic transplant&#xD;
&#xD;
          -  No current or prior evidence of graft-versus-host disease&#xD;
&#xD;
          -  No current requirement for immunosuppressive therapy Prior autologous stem cell&#xD;
             transplant allowed provided ≥ 6 months have elapsed since autologous transplant.&#xD;
&#xD;
        Eastern Cooperative Oncology Group performance status of 0, 1, or 2&#xD;
&#xD;
        Adequate bone marrow function as follows:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1,000/mm3 (without support of granulocyte colony&#xD;
             stimulating factors)&#xD;
&#xD;
          -  Platelets ≥ 50,000/mm3 (untransfused)&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
        Adequate coagulation, renal, and hepatic function as follows:&#xD;
&#xD;
          -  aPTT and PT ≤ 1.2 × upper limit of normal (ULN) for the laboratory&#xD;
&#xD;
          -  Calculated creatinine clearance ≥ 50 mL/min as calculated by the standard&#xD;
             Cockcroft-Gault equation using age, actual weight, creatinine, and gender&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 × ULN for the laboratory&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 × ULN for the laboratory. For a woman of childbearing potential&#xD;
             (WCBP), a negative serum pregnancy test performed within 7 days prior to initiation of&#xD;
             study treatment.&#xD;
&#xD;
        Note: Postmenopausal is defined as any of the following:&#xD;
&#xD;
          -  Age ≥ 60 years&#xD;
&#xD;
          -  Age &lt; 60 years and amenorrheic for at least 1 year with follicle-stimulating hormone&#xD;
             (FSH) and plasma estradiol levels in the postmenopausal range&#xD;
&#xD;
          -  Bilateral oophorectomy WCBP and male patients must agree to use a medically accepted&#xD;
             form of birth control for the duration of study treatment and for at least 1 month&#xD;
             following completion of venetoclax and/or idelalisib or 12 months following rituximab,&#xD;
             whichever occurs later.&#xD;
&#xD;
        Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A patient who meets any of the following exclusion criteria is ineligible to participate in&#xD;
        the study:&#xD;
&#xD;
        Known histologic transformation from CLL/SLL to an aggressive lymphoma (ie, Richter's&#xD;
        transformation).&#xD;
&#xD;
        Known history of drug-induced pneumonitis History of inflammatory bowel disease. Central&#xD;
        nervous system involvement Clinically significant infection including active hepatitis B or&#xD;
        hepatitis C requiring active treatment, or active CMV infection Known human&#xD;
        immunodeficiency virus (HIV) seropositivity. * Note: HIV testing is not required.&#xD;
&#xD;
        Vaccination within 4 weeks prior to initiation of rituximab *Note: Review vaccination&#xD;
        status. Patients should, if possible, be brought up-to-date with all immunizations in&#xD;
        agreement with current immunization guidelines at least 4 weeks prior to initiating&#xD;
        rituximab.•Ongoing requirement for warfarin (due to potential drug-drug interactions that&#xD;
        may increase the exposure of warfarin and ensuing complications).&#xD;
&#xD;
        Has received any of the following within 14 days prior to initiation of study&#xD;
        treatment:(NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 2ND-STEP REGISTRATION)&#xD;
&#xD;
          -  Anti-cancer therapy&#xD;
&#xD;
          -  Investigational therapy Has not recovered to ≤ grade 1 toxicity(s) from prior therapy,&#xD;
             except for chronic residual toxicities that in the opinion of the investigator are not&#xD;
             clinically relevant given the known safety/toxicity profiles of the study regimen (eg,&#xD;
             alopecia). (NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 2ND-STEP REGISTRATION) Has&#xD;
             not recovered to ≤ grade 1 toxicity(s) from idelalisib and rituximab, except for&#xD;
             chronic residual toxicities that in the opinion of the investigator are not clinically&#xD;
             relevant given the known safety/toxicity profiles of the study regimen (eg, alopecia).&#xD;
             (NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 1ST-STEP REGISTRATION)&#xD;
&#xD;
        Ongoing or planned treatment with any of the following:&#xD;
&#xD;
          -  Steroid therapy for anti-neoplastic intent&#xD;
&#xD;
          -  Strong or moderate CYP3A inhibitor or inducer, and/or a narrow-therapeutic sensitive&#xD;
             substrate&#xD;
&#xD;
          -  P-gp inhibitor or narrow-therapeutic sensitive P-gp substrate If any of these agents&#xD;
             have been used, patients must be off them for ≥ 1 week before initiation of study&#xD;
             treatment.&#xD;
&#xD;
        Prior intolerance to any component of study regimen that, in the opinion of the&#xD;
        investigator would preclude study treatment.&#xD;
&#xD;
        A cardiovascular disability status of New York Heart Association Class ≥ II Diagnosis or&#xD;
        treatment for another malignancy within 1 year of study registration, with the exception of&#xD;
        complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, any in&#xD;
        situ malignancy, or low-risk prostate cancer after curative therapy Active liver disease&#xD;
        other than lymphoid involvement, inflammatory bowel disease, or Crohn's disease&#xD;
        Malabsorption syndrome or other condition that precludes enteral route of administration.&#xD;
&#xD;
        Exhibits evidence of other clinically significant uncontrolled condition(s) including, but&#xD;
        not limited to:&#xD;
&#xD;
          -  Uncontrolled infection (viral, bacterial, or fungal)&#xD;
&#xD;
          -  Grade 3 or greater neutropenic fever within 1 week prior to initiation of study&#xD;
             treatment Active autoimmune cytopenias (for 2 or more weeks), including autoimmune&#xD;
             hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura.&#xD;
&#xD;
        Pregnancy or breastfeeding Medical, psychological, or social condition that, in the opinion&#xD;
        of the investigator, may increase the patient's risk, interfere with the patient's&#xD;
        participation in the study or hinder evaluation of study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Y Yazbek, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>venetoclax</keyword>
  <keyword>idelalisib</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

